Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View LFCR insider activity ↗

LFCRLIFECORE BIOMEDICAL, INC. \DE\

THE LATEST REPORTED YEAR

The company reported a loss.

$38.72M net loss for the year ended May 25, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$128.87MYear ended May 25, 2025
Profit or loss-$38.72MYear ended May 25, 2025
Cash from the business-$206KYear ended May 25, 2025
Total assets$229.5MAs of June 30, 2026
Total liabilities$213.41MAs of June 30, 2026
Cash & equivalents$17.24MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$524.23M
2018-05
$557.56M
2019-05
$160.07M
2020-05
$100.87M
2021-05
$111.27M
2022-05
$103.27M
2023-05
$128.26M
2024-05
$128.87M
2025-05

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
May 27, 2024 – May 25, 2025$128,867,000August 7, 202510-K ↗
May 29, 2023 – May 26, 2024$128,261,000August 7, 202510-K ↗
May 30, 2022 – May 28, 2023$103,269,000August 26, 202410-K ↗
May 31, 2021 – May 29, 2022$111,270,000August 26, 202410-K ↗
June 1, 2020 – May 30, 2021$100,874,000March 20, 202410-K ↗
May 27, 2019 – May 31, 2020$160,066,000March 16, 202310-K/A ↗
May 28, 2018 – May 26, 2019$557,559,000July 29, 202110-K ↗
May 29, 2017 – May 27, 2018$524,227,000August 14, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · Retrieved October 15, 2026

Response SHA-256: 1558a2ffe6e0c9b46b5ee698b0dbe287366a9808531f7c820d0d5517eb583dd6

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.